Industry Perspectives

The Industry Perspectives format offers sponsors a platform to present educational content from their company’s point of view in a concise, engaging 8–10-minute video presentation. These presentations are delivered by a key opinion leader or a member of the company’s medical or executive team, providing valuable insights and expertise.

Explore the presentations below to access high-quality content from our industry partners.

MyProstateScore 2.0 (MPS2): A Novel, Noninvasive Urine Test Prior to Prostate Biopsy

Jeffrey J. Tosoian, MD, MPH, introduces the MyProstateScore 2.0 test as a non-invasive urine-based diagnostic tool for prostate cancer.

Industry Perspective: Cxbladder Triage AUA Microhematuria Guidelines Inclusion

Jay K. Jhaveri, MD, MPH, discusses the key changes in the 2025 AUA microhematuria guidelines and their implications for clinical practice.

UroVation Interview: Envision Sciences – Advancing Cancer Diagnosis and Prognosis

GRU UroVations: Dr. Crawford and Steven Stone, PhD, Envision Sciences, Salt Lake City, Utah, discuss IHC Biomarkers in prostate cancer.

Expert Discussion on LDR Brachytherapy for Prostate Cancer

Drs. Keyes, Kurtzman, and Crawford highlight how LDR brachytherapy improves patient outcomes and collaboration between urologists and radiation oncologists.

Connected Care and Latest Developments in Prostate Cancer Management

Ilya Gipp, MD, PhD, discusses innovative diagnostic and therapeutic approaches in prostate cancer management.

Understanding Metastatic Castration-Resistant Prostate Cancer

Shell Liang, PhD, discusses metastatic castration-resistant prostate cancer (mCRPC), which does not respond to androgen deprivation therapy (ADT).

Emergent Applications of Prostate Cancer Mapping with Artificial Intelligence

Alan Priester, PhD explores the applications of artificial intelligence (AI) in mapping prostate cancer and precision diagnosis and treatment.

Convergent Therapeutics: Next-Generation Targeted Radiotherapies

Philip Kantoff, MD, explores advancements in targeted radiotherapies and their potential to revolutionize prostate cancer treatment.

Diagnostic and Prognostic Biomarkers for Prostate Cancer

Ericka Bagi, BSN, RN, discusses diagnostic and prognostic biomarkers in prostate cancer.

Industry Perspective: Illuccix® for Gallium-68-PSMA-11 PET Imaging of Prostate Cancer

Bradley Fehrenbach, MD, MBA, presents Illuccix® for Gallium-68-PSMA-11 PET Imaging of PCa, supported by Telix Pharmaceuticals.

Industry Perspective: BioProtect Balloon Implant™ System

Daniel Y. Song, MD, compares the BioProtect Balloon Implant™ System to current rectal spacers in this presentation, sponsored by BioProtect.

Prostate Cancer Detection-Integrated Clinical Solution

Donald Baker, R.T.(R)(CT)(MR), discusses prostate cancer detection and the implementation of an integrated clinical solution.